{"id":11603,"date":"2025-07-26T10:55:29","date_gmt":"2025-07-26T08:55:29","guid":{"rendered":"https:\/\/valintermed.com\/?p=11603"},"modified":"2025-07-26T10:55:29","modified_gmt":"2025-07-26T08:55:29","slug":"nasledstvennaya-tserebralnaya-amiloidnaya-angiopatiya","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-cerebral-amygdalafil-angiopatiya\/","title":{"rendered":"Hereditary cerebral amyloid angiopathy"},"content":{"rendered":"
<\/div>\n

Hereditary cerebral amyloid angiopathy (HCAA) is a disease characterized by the deposition of amyloid protein in the walls of brain vessels, which can lead to their weakness and predisposition to strokes. The condition can manifest itself with various neurological symptoms, including seizures, cognitive impairment, and stroke. Genetic predisposition plays a key role in the development of HCAA, making it a hot topic for medical research. The disease poses a significant burden to both the healthcare system and patients and their families, which requires a thorough understanding of its mechanisms, diagnosis, and treatment methods.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n